Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — 9th Annual Australian Microcap Investment Conference 2018
18 slides from Elixinol Wellness's conference presentation, Oct 17, 2018
Slide 1: Elixinol Global Limited – 9th Annual Australian Microcap Investment Conference
For personal use only DRAFT Elixinol Global Limited 9th Annual Australian Microcap Investment Conference – October 2018 ASX: EXL; OTCQX: ELLXF | www.elixinolglobal.com
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Group Limited (EXL) and its subsidiaries and their activities. The information in this For personal use only presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuou
Slide 3: Our products
Our products For personal use only ** * Elixinol is a supplier of bulk CBD to the Pet Releaf range of products as well as providing private label finished goods production services and is also a distributor Page 3 of Pet Releaf Company Presentation products. February 2018 Elixinol in the USA exports
Slide 4: Investment highlights
Investment highlights • Elixinol Global (ASX: EXL) listed in January 2018 with strong institutional support For personal use only • EXL is a diversified business with two established consumer product brands in fast growing markets: • Elixinol – US based seller of cannabidiol-based dietary supplement
Slide 5: Board and management team and market data
Board and management team and market data A senior team, experienced in complex regulatory operating environments For personal use only Board and management team Elixinol Global market data Andrew Duff | Non-Executive Chairman (ASX: EXL; OTCQX: ELLXF) Experienced ASX listed company director. Ex CFO
Slide 6: Diversified portfolio
Diversified portfolio 1H FY2018 revenue by business unit For personal use only Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medicinal Cannabis Revenue $12.54m (84%) Revenue $2.34m (16%) Seeking licence and permit Submitted licence applications for cultivation and manufacture to Au
Slide 7: Diversified across three rapidly growing markets
Diversified across three rapidly growing markets Businesses positioned within major growth themes For personal use only Hemp derived CBD – US market Hemp derived foods – global market Medicinal cannabis – Australian size and projections size and projections+ market projections Developing multi-billi
Slide 8: Hemp and cannabis – rapidly evolving landscape
Hemp and cannabis – rapidly evolving landscape A tide of change is sweeping through hemp and cannabis industries, led by global governments For personal use only 2018 onwards Hemp industry awaits 2014 2014 US Farm Bill signing Agricultural Act of Elixinol starts 2017 2014 (Farm Bill) trading in the
Slide 9: Key financial highlights for 1H FY2018
Key financial highlights for 1H FY2018 1 Revenue 1H FY2018 $14.9m vs 1H FY2017 $7.1m, 110% growth H1 FY18 – EXL isUnderlying positioned for strong, EBITDA continued growth 1H FY2018 $0.8m vs 1H FY2017 ($0.1)m loss For personal use only Group results 1H FY2018 Underlying NPAT 1H FY2018 $0.6m vs 1H FY
Slide 10: Elixinol Global 1H FY2018 growth initiatives
Elixinol Global 1H FY2018 growth initiatives Disciplined approach to drive future growth For personal use only • Investment in farming and production capabilities to facilitate future growth • Key sales hires focused on retail distribution which is higher margin • Continued focus on core products an
Slide 11: Elixinol Global international footprint
Elixinol Global international footprint An established platform that can be leveraged for consumer products For personal use only Global platform for growth • Avenues to market established in 40 countries with mix of direct sales and via distribution partners • Facilities (pins) in: • Sydney and Ban
Slide 12: Elixinol USA: positioned for future growth
Elixinol USA: positioned for future growth Increased capacity and product development to drive earnings and margin improvement For personal use only • Elixinol USA is relocating to a new facility in Colorado, USA, designed to be GMP certified and will more than double the usable capacity for process
Slide 13: Elixinol USA: focus for next months
Elixinol USA: focus for next 12 months Focus on strong growth in home markets, new product development and marketing For personal use only • Grow market share in US; deliver growth in attractive markets (Europe, Asia) • Scale teams to support expanded business • Deploy and optimize new US-based plan
Slide 14: Hemp Foods Australia: industry leader
Hemp Foods Australia: industry leader Focus on growth of core products and new product offerings For personal use only • Core product range includes hemp oils, flours, seeds, protein • currently sold via e-commerce and health food shops • Hemp Foods Australia supplying to major FMCG brands including
Slide 15: Hemp Foods Australia: focus for next months
Hemp Foods Australia: focus for next 12 months Strong growth in Australia, driving raw and finished product sales via multi-channel approach For personal use only • Grow Australian market share and secure top 1 position for hemp food branded products • Select Hemp Foods Australia owned brands to be
Slide 16: Elixinol Australia (medicinal cannabis)
Elixinol Australia (medicinal cannabis) Advanced development plans are prepared For personal use only • Strategy to enter Australian medicinal cannabis market and develop export capability • Submitted licence applications for cultivation and manufacture to the Office of Drug Control (ODC) in Awaitin
Slide 17: Strategic outlook: delivering on our corporate strategy
Strategic outlook: delivering on our corporate strategy Capturing substantial global growth opportunity in hemp-CBD and medicinal cannabis For personal use only FY2021 FY2020 • Global top 3 leadership position in CBD FY2019 • Globally diversified, vertically integrated CBD consumer products consumer
Slide 18: For more information
For personal use only For more information: Paul Benhaim Ron Dufficy Chief Executive Officer Chief Financial Officer DRAFT paul@elixinolglobal.com ron.dufficy@elixinolglobal.com +61 407 767 709 +61 428 881 718
Elixinol Global — 9th Annual Australian Microcap Investment Conference 2018 on 6ix